Blood test guides anal cancer treatment: less side effects, better survival?

NCT ID NCT07425054

First seen Feb 20, 2026 · Last updated May 14, 2026 · Updated 8 times

Summary

This study tests a personalized approach for anal cancer. Instead of giving everyone the same dose of chemoradiation, doctors will use a blood test (ctDNA) to see how the tumor is responding. People whose cancer responds well get a lower dose to reduce side effects; those who don't respond as well get a higher dose and may also receive the immunotherapy drug retifanlimab. The goal is to improve survival and reduce side effects. The study plans to enroll 33 people who have not yet been treated.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center

    Cleveland, Ohio, 44106, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.